What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? (Q26824136)

6

0 references

author name string

Ross T. Campbell

1

1 reference

Pardeep S. Jhund

2

1 reference

Nathaniel M. Hawkins

4

1 reference

Mark C. Petrie

5

1 reference

language of work or name

1 reference

11 December 2012

1 reference

Journal of the American College of Cardiology

published in

1 reference

volume

60

1 reference

issue

23

1 reference

page(s)

2349-56

1 reference

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Comparison of characteristics and outcomes of asymptomatic versus symptomatic left ventricular dysfunction in subjects 65 years old or older (from the Cardiovascular Health Study)

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

HFNEF breathlessness: is it really heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Heart failure with normal left ventricular ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Treatment of heart failure with normal ejection fraction: an inconvenient truth!

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Outcome of heart failure with preserved ejection fraction in a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Trends in prevalence and outcome of heart failure with preserved ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Treatment of hypertension in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Irbesartan in patients with heart failure and preserved ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Irbesartan in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Epidemiology and clinical course of heart failure with preserved ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure".

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Resting global and regional left ventricular contractility in patients with heart failure and normal ejection fraction: insights from speckle-tracking echocardiography.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021

Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2012.04.064

7 January 2021